Ignite Creation Date:
2024-05-06 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05335876
Status:
RECRUITING
Last Update Posted:
2024-05-24
First Post:
2022-04-12
Brief Title:
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Spinal Muscular Atrophy SMA |
Keywords:
| Name | View |
|---|---|
| onasemnogene abeparvovec | View |
| Zolgensma | View |
| OAV101 | View |
| AVXS 101 | View |
| gene therapy | View |
| Muscle atrophy | View |
| SBMA | View |
| spinal and bulbar muscular atrophy | View |
| spinal muscular atrophy | View |
| bulbar muscular atrophy | View |
| muscle function | View |
| myopathy | View |
| muscle wasting | View |
| atrophied muscle | View |
| loss of muscle strength | View |
| Spinal Muscular Atrophy SMA | View |
| survival motor neuron 1 gene SMN1 | View |
| SMN protein depletion | View |
| survival motor neuron 2 gene SMN2 | View |
| chromosome 5q13 | View |
| neurogenetic disorder | View |